Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.

Pharmacogenomics - 1 Apr 2018

Xiao Wenjing, Guo Jian-Ping, Li Chun, Ye Hua, Wei Wei, Zou Yaohong, Dai Lie, Li Zhijun, Zhang Miaojia, Li Xiangpei, Cai Xiaoyan, Zhao Jianhong, Wang Youlian, Tao Yi, Liu Dongzhou, Li Yasong, Wu Min, Sun Erwei, Wu Lijun, Luo Li, Mu Rong, Li Zhanguo

Abstract excerpt

Iguratimod (IGU) is a novel disease-modifying anti-rheumatic drug (DMARD) in rheumatoid arthritis (RA). Like other DMARDs, IGU exhibited significant differences in effectiveness and safety. AIM: The aim of this study was to identify genetic predictorsof efficacyand toxicity of IGU in patients with RA. MATERIALS & METHODS: Seven SNPs from IGU-metabolizing genes were genotyped in 272 IGU-treated patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Arthritis, Rheumatoid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromones

Share to Genetic Carrier Screening

Share to Heterozygote

Share to Predictive Value of Tests

Share to Risk Assessment

Share to Sulfonamides

Source

Identifiers

PMID: 29517409
DOI: 10.2217/pgs-2017-0162

Genes

ABCG2
NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.PMID 29517409Read ↗

Pharmacogenetics of therapies in rheumatoid arthritis: An update.Semantic proximity Read ↗

Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis.Semantic proximity Read ↗

Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients.Semantic proximity Read ↗

Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.Semantic proximity Read ↗

Pharmacogenomics in rheumatoid arthritis.Semantic proximity Read ↗

Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.Semantic proximity Read ↗

Genetic polymorphisms associated with therapeutic response and adverse effects to methotrexate in Taiwanese patients with rheumatoid arthritis: a real-world, hospital-based study.Semantic proximity Read ↗

Pharmacogenetics and pharmacogenomics in rheumatology.Semantic proximity Read ↗

Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?Semantic proximity Read ↗

Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis.Semantic proximity Read ↗

Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.